SCHEMBL6779446

SCHEMBL6779446

COc1cc(C=O)c(-c2c(OC)cccc2OC)cc1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 11/20 0.54
TLR2 O60603 1/20 0.54
TLR1 Q15399 1/20 0.54
TLR6 Q9Y2C9 1/20 0.54
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
ALDH1A1 P00352 4/20 0.46
TDP1 Q9NUW8 2/20 0.46
HPGD P15428 2/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
AOX1 Q06278 1/20 0.46
TRIM24 O15164 1/20 0.46
ALDH5A1 P51649 1/20 0.46
ABAT P80404 1/20 0.46
TRIM33 Q9UPN9 1/20 0.46
EGFR P00533 1/20 0.45
PIM1 P11309 1/20 0.45
KDM4E B2RXH2 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6780861 0.87 ERN1 (0.51) ERN1TLR2TLR1TLR6ALDH1A1
SCHEMBL6782462 0.84 ERN1 (0.58) ERN1TLR2TLR1TLR6MEN1
SCHEMBL6536370 0.81 ERN1 (0.51) ERN1TLR2TLR1TLR6ALDH1A1
SCHEMBL6780747 0.80 ERN1 (0.48) ERN1TLR2TLR1TLR6MEN1
SCHEMBL6782947 0.79 ERN1 (0.49) ERN1TLR2TLR1TLR6MEN1
SCHEMBL6535891 0.79 ERN1 (0.49) ERN1TLR2TLR1TLR6ALDH1A1
SCHEMBL6777394 0.78 ERN1 (0.61) ERN1TLR2TLR1TLR6ALDH1A1
SCHEMBL6535907 0.78 ERN1 (0.61) ERN1TLR2TLR1TLR6MEN1
SCHEMBL6783006 0.78 ERN1 (0.51) ERN1TLR2TLR1TLR6ALDH1A1
SCHEMBL6536111 0.78 ERN1 (0.61) ERN1TLR2TLR1TLR6MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6825208-B2 SELECTIVE INHIBITORS OF SERINE PROTEASE ENZYMES, ESPECIALLY FACTOR VIIA; MODULATION OF THE COAGULATION CASCADE. BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-11-30 US disclosed
US-20030225110-A1 Tetrahydroquinoline derivatives as antithrombotic agents BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225110-A1 Tetrahydroquinoline derivatives as antithrombotic agents TFPI, TFPI2, SERPINC1 ERN1 1774/4885TLR2 4537/4885TLR1 3900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.